Broadly neutralizing antibodies against influenza A viruses, Fully human, 39.29, gedivumab, MHAA4549A

$1,999.00
In stock
Catalog
A90003
Bulk Inquiry

Broadly neutralizing antibodies against influenza A viruses, Fully human, 39.29, gedivumab, MHAA4549A

Clone 39.29         Catalog#: A90003

 

Description: 39.29 (gedivumab) is fully human neutralizing monoclonal antibody against influenza A. 39.29 is a neutralizing monoclonal antibody that recognizes the hemagglutinin (HA) glycoprotein of all 16 subtypes and neutralized both group 1 and group 2 influenza A viruses. 39.29  may be used for passive protection and to inform vaccine design because of its broad specificity and neutralization potency.

 

 

Isotype:

IgG1

Species reactivity:

Human

Production:

Tissue culture

Purification:

Protein A

Applications:

Neutralization assay, In vivo protection etc.

Storage: 

Store at +4°C short term (1-2 weeks). Store at -20°C long term.

Formulation:

PBS, pH 7.4, Filter sterilized. Endotoxin level tests less than 0.06 EU/ug.

Clonality:

Monoclonal

 

Reference:                           

  1. Nakamura G, et al. (2013). An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies.Cell Host Microbe. 2013 Jul 17;14(1):93-103.
  2. Deng R,et al. (2018). Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.Clin Pharmacokinet. 2018 Mar;57(3):367-377.
Write Your Own Review
You're reviewing:Broadly neutralizing antibodies against influenza A viruses, Fully human, 39.29, gedivumab, MHAA4549A
Your Rating